サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1629868

定量吸入器の世界市場（2025年～2033年）

Global Metered-Dose Inhalers Market - 2025-2033

出版日
ページ情報
英文 176 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
定量吸入器の世界市場（2025年～2033年）
出版日: 2024年12月30日
発行: DataM Intelligence
ページ情報: 英文 176 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の定量吸入器市場は、2023年に166億米ドルに達し、2033年には241億8,000万米ドルに達し、予測期間2025年～2033年のCAGRは4.8％で成長すると予測されています。

定量吸入器は、加圧されたキャニスターを通して肺に薬剤を供給する装置です。吸入されると、手動または自動で放出されます。一部の吸入器には、残りの投与量を追跡するためのカウンターが付いています。ドライパウダー吸入器（DPI）は呼吸作動型であり、吸入器を通して深く速い呼吸をしたときにのみ薬剤が放出されます。

市場力学：

促進要因と抑制要因

技術進歩の台頭

定量吸入器（MDI）市場は、技術の進歩により成長しています。最新のMDIは、統合用量カウンター、スマートコネクティビティ、呼吸作動機構を備えており、不適切な投与量や患者のアドヒアランスといった問題に対処しています。これらの技術革新は、特に喘息やCOPDのような慢性疾患にとって有益です。環境に優しい推進剤への移行は、世界の持続可能性の目標に沿うものであり、効果的なドラッグデリバリーを保証するものです。これらの改善により、使用感、安全性、治療成績が向上し、アドバンストMDIの需要を牽引しています。

例えば、アセプティカは2024年6月、加圧式定量吸入器（pMDI）とドライパウダー吸入器（DPI）の両方に対応するスマート吸入器用量トラッカー、PUFFClicker3を発売しました。このデバイスは、両方のタイプの101のSNOMEDコード化された吸入器をサポートし、吸入器の切り替えを簡単なプロセスにします。各吸入器に対してグラフィカルな指示を提供し、あらゆる年齢層および吸入器治療を必要とする呼吸器疾患の患者の吸入アドヒアランスの向上を目指します。

厳しい規制要件

世界の定量吸入器市場は、FDAやEMAのような当局による厳しい規制要件のために大きな課題に直面しています。これらの規制は、MDIの安全性、有効性、品質を保証するために厳格な試験プロトコルを義務付けています。環境に優しい推進剤への移行は承認プロセスを複雑にしており、広範な調査とコンプライアンス対策を必要としています。規制当局による承認の遅れは製品の上市を妨げ、市場力学に影響を与える可能性があります。また、地域によって規制の枠組みが異なることも、世界展開の課題となっており、既存企業と新興企業の両方に障壁をもたらし、技術革新と市場成長を制限しています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 技術進歩の高まり
    • 抑制要因
      • 厳格な規制要件
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 製品タイプ別

  • 呼吸作動型加圧吸入器
  • 手動加圧吸入器
  • ソフトミスト吸入器

第7章 用途別

  • 喘息
  • 慢性閉塞性肺疾患（COPD）
  • その他

第8章 エンドユーザー別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 中東・アフリカ

第10章 競合情勢

  • 競合シナリオ
  • 市況・シェア分析
  • M&A分析

第11章 企業プロファイル

  • Sunovion Pharmaceuticals Inc
    • 会社概要
    • 製品ポートフォリオと概要
    • 財務概要
    • 主な発展
  • AstraZeneca
  • Boehringer Ingelheim
  • Covis Pharma B.V.
  • GlaxoSmithKline
  • Kindeva Drug Delivery LP
  • Teva Phamrmaceuticals
  • Norton Waterford LTD
  • Armstrong Pharmaceuticals Inc
  • Cipla LTD

第12章 付録

目次
Product Code: MD8902

The global metered-dose inhalers market reached US$ 16.6 billion in 2023 and is expected to reach US$ 24.18 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2025-2033.

A metered-dose inhaler is a device that delivers medication into the lungs through a pressurized canister. It can be released manually or automatically when inhaled. Some inhalers have counters to track remaining doses. Dry powder inhalers (DPI) are breath-activated, releasing medication only when a deep, fast breath is taken through the inhaler.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

The market for metered dose inhalers (MDIs) is growing due to technological advancements. Modern MDIs feature integrated dose counters, smart connectivity, and breath-actuated mechanisms, addressing issues like improper dosage and patient adherence. These innovations are particularly beneficial for chronic conditions like asthma and COPD. The shift to environmentally friendly propellants aligns with global sustainability goals and ensures effective drug delivery. These improvements are enhancing user experience, safety, and therapeutic outcomes, driving demand for advanced MDIs.

For instance, in June 2024, Aseptika has launched the PUFFClicker3, a smart inhaler dose tracker compatible with both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI). The device supports 101 SNOMED-coded inhalers for both types, making inhaler switching a simple process. It provides graphical instructions for each inhaler, aiming to improve inhaler adherence for patients of all ages and respiratory conditions requiring inhaler treatment.

Stringent Regulatory Requirements

The global metered-dose inhalers market faces significant challenges due to stringent regulatory requirements from authorities like the FDA and EMA. These regulations mandate rigorous testing protocols to ensure safety, efficacy, and quality of MDIs. Transitioning to eco-friendly propellants has complicated the approval process, requiring extensive research and compliance measures. Delays in regulatory approvals can hinder product launches, impacting market dynamics. Variations in regulatory frameworks across regions also pose challenges for global expansion, creating barriers for both established and emerging players, limiting innovation and market growth.

Segment Analysis

The global metered-dose inhalers market is segmented based on product type, application, end user and region.

Product type:

Breath-Actuated Pressurized Inhalers segment is expected to dominate the metered-dose inhalers market share

The breath-actuated pressurized segment holds a major portion of the metered-dose inhalers market share and is expected to continue to hold a significant portion of the metered-dose inhalers market share during the forecast period.

Breath-actuated pressurized metered-dose inhalers (BAIs) are gaining prominence in the global MDI market due to their ability to address the challenge of coordination between inhalation and actuation. Traditional MDIs require patients to synchronize their breathing with the device's drug release, which can be difficult for certain populations, such as elderly patients and children. BAIs automatically release medication when the patient inhales, ensuring optimal drug delivery and improving therapeutic outcomes. They are particularly useful for chronic respiratory conditions like asthma and COPD, where long-term treatment compliance is crucial.

For instance, in November 2023, Berry Global Healthcare has introduced the PneumoHaler, a lightweight, breath-actuated inhaler designed for managing asthma and COPD. This multi-dose inhaler is designed to eliminate the need for pharmaceutical companies to develop their own platforms, allowing faster-to-market solutions. The PneumoHaler also improves medication administration by addressing poor user technique of pressurized metered dose inhalers.

Application:

Asthma segment is the fastest-growing segment in metered-dose inhalers market share

The asthma segment is the fastest-growing segment in the metered-dose inhalers market share and is expected to hold the market share over the forecast period.

Asthma is a major global market driver due to its high prevalence and the need for long-term management solutions. With over 260 Billion people affected by asthma, the demand for MDIs is increasing due to factors like urbanization, air pollution, and climate change. MDIs provide rapid drug delivery to the airways, relieving symptoms like wheezing and chest tightness. Advanced formulations, such as corticosteroids and combination therapies, have expanded treatment options. Government health initiatives and awareness campaigns support early diagnosis and management of asthma, further boosting demand for MDIs. Asthma's global burden directly influences the MDI market's growth trajectory.

For instance, in July 2023, Lupin has introduced Luforbec, a pressurized metered dose inhaler, for the treatment of asthma and COPD in Germany. Hormosan Pharma GmbH, a subsidiary of Lupin, has introduced Luforbec in the country. The product is suitable for adult asthma and COPD treatment, where an inhaled corticosteroid and long-acting beta2-agonist is used.

Geographical Analysis

North America is expected to hold a significant position in the metered-dose inhalers market share

North America holds a substantial position in the metered-dose inhalers market and is expected to hold most of the market share due to the rising prevalence of respiratory diseases like asthma and COPD in North America, combined with an aging population, has led to a greater need for effective treatment options. MDIs are one of the most commonly prescribed devices for managing these conditions. The high level of healthcare awareness, better access to medical facilities, and well-established healthcare infrastructure in the region support the demand for advanced inhaler technologies. Major pharmaceutical companies in North America continuously innovate to improve inhaler designs and formulations, including smart inhalers with dose counters and tracking capabilities, which improve patient compliance and make MDIs the treatment of choice for many.

For instance, according to National Heart, Lung and Blood Institute, COPD, a combination of emphysema and chronic bronchitis, affects over 14 billion adults in the US, with over half being women. The severity of each condition varies. COPD rates are higher in American Indian and Alaska Native communities and rural areas. It is a major cause of disability and the sixth leading cause of death in the US, according to the Centers for Disease Control and Prevention.

Europe is growing at the fastest pace in the metered-dose inhalers market

Europe holds the fastest pace in the metered-dose inhalers market and is expected to hold most of the market share due to the FDA approvals, increasing prevalence of respiratory diseases like asthma and COPD. The aging population and increased exposure to environmental pollutants contribute to this demand. The European Union's strict regulatory standards, focusing on eco-friendly propellants and sustainability, are driving innovation in the inhaler market. Government initiatives promoting early diagnosis and effective management of these diseases further support MDI demand. Healthcare reimbursement systems in Europe ensure patients have access to necessary treatments, including MDIs.

For instance, in January 2024, Avillion LLP, a drug development company, has received FDA approval for AstraZeneca's Airsupra, a first-in-class, pressurised metered-dose inhaler (pMDI) and rescue medication. Airsupra is designed to treat bronchoconstriction and reduce exacerbations in people aged 18 and older with asthma. The FDA approved Airsupra, which contains albuterol and budesonide, a short-acting beta2-agonist.

Moreover, the region's focus on medical technology and collaborations between healthcare institutions and pharmaceutical companies has led to continuous improvements in MDI design, enhancing user experience and therapeutic efficacy.

Competitive Landscape

The major global players in the metered-dose inhalers market include Sunovion Pharmaceuticals Inc, AstraZeneca, Boehringer Ingelheim, Covis Pharma B.V., GlaxoSmithKline, Kindeva Drug Delivery LP, Teva Phamrmaceuticals, Norton Waterford LTD, Armstrong Pharmaceuticals Inc, Cipla LTD and among others.

Key Developments

  • In November 2023, GSK plc is set to begin Phase III trials of a low carbon version of its metered dose inhaler, Ventolin (salbutamol), in 2024. If successful, it could reduce greenhouse gas emissions by around 90%, contributing to GSK's net-zero climate targets. The inhaler, used by 35 Billion patients worldwide, accounts for 49% of GSK's carbon footprint and contributes to global health systems' carbon footprint. Reducing the propellant's carbon footprint is a key milestone in the company's journey to net zero.
  • In September 2024, AstraZeneca has completed studies for the transition of Breztri/Trixeo Aerosphere, a triple-combination therapy for chronic obstructive pulmonary disease, to a new propellant with 99.9% lower Global Warming Potential than current inhaled medicines. Breztri will be the first medicine in AstraZeneca's pressurised-metered dose inhalers (pMDIs) to transition to the new propellant. Clinical programs are underway for the transition of AstraZeneca's wider pMDI portfolio.

Emerging Players

The emerging players in the metered-dose inhalers market include Propeller Health (digital inhaler technology), Adherium (smart inhaler systems), Amiko Digital Health Limited and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global metered-dose inhalers market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Requirements
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 6.1.2. Market Attractiveness Index, By Product type
  • 6.2. Breath-Actuated Pressurized Inhalers*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Manually-Actuated Pressurized Inhalers
  • 6.4. Soft Mist Inhalers

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Asthma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Chronic Obstructive Pulmonary Disease (COPD)
  • 7.4. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospital Pharmacies*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacies
  • 8.4. Online Pharmacies

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Sunovion Pharmaceuticals Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. AstraZeneca
  • 11.3. Boehringer Ingelheim
  • 11.4. Covis Pharma B.V.
  • 11.5. GlaxoSmithKline
  • 11.6. Kindeva Drug Delivery LP
  • 11.7. Teva Phamrmaceuticals
  • 11.8. Norton Waterford LTD
  • 11.9. Armstrong Pharmaceuticals Inc
  • 11.10. Cipla LTD

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us